The Acute heart failure (AHF) - Market Insights, Epidemiology and Market Forecast-2022 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. According to DelveInsight, the global AHF market was $188 million in 2015 and expected to grow to $929 million by 2020 with and compound annual growth rate (CAGR) of 17%.
Acute Heart Failure (AHF) is the rapid onset of sign and symptoms of Heart Failure resulting in need and urgent therapy or hospitalization. The AHF primarily includes the symptoms of pulmonary congestion or peripheral perfusion due to cardiac or vascular dysfunction. Based on the recommended guidelines, loop diuretics are the most common treatment for the Acute Heart Failure in patients with dyspnoea caused by pulmonary oedema, more than 90% of patients admitted with AHF receives this drug.
Key Coverage and Benefits:
• The report will help in developing business strategies by understanding the trends shaping and driving the global Acute heart failure (AHF) market.
• Identifying patient populations in the global Acute heart failure (AHF) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Acute heart failure (AHF) therapeutics in each of the markets covered.
• To understand the future market competition in the global Acute heart failure (AHF) therapeutics market and Insightful review of the key market drivers and barriers.
Scope of the Report:
•
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2022.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2022.
• It also provides Acute heart failure (AHF) for United States, EU5 and Japan from 2015 and forecasted Market to 2022.
'
Table of Contents
Report Introduction
Executive Summary
Key findings
Acute Heart Failure Market Overview at a Glance
Worldwide Market Size of Acute Heart Failure in 2015 (MM)
Worldwide Market Size of Acute Heart Failure in 2022 (MM)
Acute Heart Failure
Disease Overview
Treatment Goals
Management
Treatment Algorithms
Epidemiology and Patient Population
Key Findings
Overview
Diagnosed Hospitalization Cases of Acute Heart Failure
United States
5EU and Japan
Total number of Hospitalization Cases for Acute Heart Failure in 7 Major Markets
Current Clinical Practice
Conventional Therapies for Acute Heart Failure Management
In Cases of Pulmonary Oedema
In cases of Hypotension and Cardiogenic Shock
In case of Hypertension
Treatment after Stabilization
Acute Novel Therapies
Carperitide
Product Profile
Advantages & Disadvantages
Cost of Therapy
Drug Sales
Carperitide Historical Sales and Forecasted Sales (2015-2022)
Acute Heart Failure-Global Market Assessment
Key Findings
Global Acute Heart Failure Market
Market Overview
Global Market Sales by Treatment Setting in AHF, 2015-2022
Total Acute Heart Failure Drug Sales
Timeline of Key Market events for Acute Heart Failure
Acute Heart Failure-United States Market Assessment
US Market Overview
United States Market Sales by Treatment Setting in AHF, 2015-2022
United States Market Share by Treatment Setting in AHF, 2015-2022
Acute Heart Failure-France Market Assessment
France Market Overview
France Market Sales by Treatment Setting in AHF, 2015-2022
France Market Share by Treatment Setting in AHF, 2015-2022
Acute Heart Failure-Germany Market Assessment
Germany Market Overview
Germany Market Sales by Treatment Setting in AHF, 2015-2022
Germany Market Share by Treatment Setting in AHF, 2015-2022
Acute Heart Failure-Italy Market Assessment
Italy Market Overview
Italy Market Sales by Treatment Setting in AHF, 2015-2022
Italy Market Share by Treatment Setting in AHF, 2015-2022
Acute Heart Failure-Spain Market Assessment
Spain Market Overview
Spain Market Sales by Treatment Setting in AHF, 2015-2022
Spain Market Share by Treatment Setting in AHF, 2015-2022
Acute Heart Failure-United Kingdom Market Assessment
United Kingdom Market Overview
United Kingdom Market Sales by Treatment Setting in AHF, 2015-2022
United Kingdom Market Share by Treatment Setting in AHF, 2015-2022
Acute Heart Failure-Japan Market Assessment
Japan Market Overview
Japan Market Sales by Treatment Setting in AHF, 2015-2022
Japan Market Share by Treatment Setting in AHF, 2015-2022
Market Drivers and Market Constraints
Factors driving the market for Acute Heart Failure
Factors constraining the market for Acute Heart Failure
Emerging Therapies
Key findings
Unmet Need
Pipeline Overview
Product Profiles (Phase III)
Ularitide: Cardiorentis
Product Description:
Research and Development
Product Development Activities:
Serelaxin: Novartis Pharmaceuticals
Product Description:
Research and Development
Product Development Activities:
Product Profiles (Phase II)
CXL 1427: Bristol-Myers Squibb
Product Description:
Research and Development
Product Development Activities:
TRV 027: Trevena
Product Description:
Research and Development
Product Development Activities:
Omecamtiv mecarbil: Amgen
Product Description:
Research and Development
Product Development Activities:
Post Acute Heart Failure Management Therapy
Cenderitide: Capricor Therapeutics
Product Description:
Research and Development
Product Development Activities:
Side Effects associated with the Emereging Therapies
Forecasting Outlook
Global Market size of Acute Heart Failure
Global Acute Heart Failure Therapy Sales
Dosage, Days of Therapy and Compliance
Prices Sources & Assumptions
Consulting Services
Disclaimer
About DelveInsight
List of Tables
Table 1: Global (7MM) Epidemiology (N)
Table 2: Total Hospitalizations for Acute HF (Men and Women ≥45 Years) (2015-2022)
Table 3: Carperitide Historical Sales and Forecasted Sales (2015-2022) (USD MM)
Table 4: Global Acute Heart Failure Sales- 2015-2022 (USD MM)
Table 5: AHF Total Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
Table 6: Timeline of Key Events in Acute Heart Failure
Table 7: United States Acute Heart Failure Sales- 2015-2022 (USD MM)
Table 8: AHF United States Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
Table 9: France Acute Heart Failure Sales- 2015-2022 (USD MM)
Table 10: AHF France Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
Table 11: Germany Acute Heart Failure Sales- 2015-2022 (USD MM)
Table 12: AHF Germany Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
Table 13: Italy Acute Heart Failure Sales- 2015-2022 (USD MM)
Table 14: AHF Italy Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
Table 15: Spain Acute Heart Failure Sales- 2015-2022 (USD MM)
Table 16: AHF Spain Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
Table 17: United Kingdom Acute Heart Failure Sales- 2015-2022 (USD MM)
Table 18: AHF United Kingdom Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
Table 19: Japan Acute Heart Failure Sales- 2015-2022 (USD MM)
Table 20: AHF Japan Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
Table 21: Side Effects associated with Emerging Therapies (Phase III & Phase II)
Table 22: Global Market Size of Acute Heart Failure by Country
Table 23: Global Acute Heart Failure Sales by Therapy
Table 24: Acute Heart Failure Therapy- Dosage, Days of Therapy and Compliance
Table 25: Pricing Sources & Assumptions
List of Figures
Figure 1: Normotensive AHF (SBP 90-140 mmHg)
Figure 2: Hypotensive AHF (SBP<90mmHg)
Figure 3: Hypertensive AHF (SBP>140mmHg)
Figure 4:Diagnosed Hospitalization Cases of Acute Heart Failure in 7 MM-(2015-2022)
Figure 5: Total Hospitalization Cases and Diagnosed rate for Acute HF (Men and Women ≥45 Years) (2015-2022)
Figure 4: Carperitide Historical Sales and Forecasted Sales (2015-2022) (USD MM)
Figure 1: Global Acute Heart Failure Sales- 2015-2022 (USD MM)
Figure 2: AHF Global Sales by Treatment Setting- 2015-2022
Figure 9: AHF Total Therapy Sales by Treatment Setting- 2015-2022 (USD MM)
Figure 3: United States Acute Heart Failure Sales- 2015-2022 (USD MM)
Figure 4: AHF United States Sales by Treatment Setting- 2015-2022 (USD MM)
Figure 5: AHF United States Sales Patient Share by Treatment Setting- 2015-2022 (%)
Figure 6: France Acute Heart Failure Sales- 2015-2022 (USD MM)
Figure 7: AHF France Sales by Treatment Setting- 2015-2022 (USD MM)
Figure 8: AHF France Sales Patient Share by Treatment Setting- 2015-2022 (%)
Figure 9: Germany Acute Heart Failure Sales- 2015-2022 (USD MM)
Figure 10: AHF Germany Sales by Treatment Setting- 2015-2022 (USD MM)
Figure 11: AHF Germany Sales Patient Share by Treatment Setting- 2015-2022 (%)
Figure 12: Italy Acute Heart Failure Sales- 2015-2022 (USD MM)
Figure 13: AHF Italy Sales by Treatment Setting- 2015-2022 (USD MM)
Figure 14: AHF Italy Sales Patient Share by Treatment Setting- 2015-2022 (%)
Figure 15: Spain Acute Heart Failure Sales- 2015-2022 (USD MM)
Figure 16: AHF Spain Sales by Treatment Setting- 2015-2022 (USD MM)
Figure 17: AHF Spain Sales Patient Share by Treatment Setting- 2015-2022 (%)
Figure 18: United Kingdom Acute Heart Failure Sales- 2015-2022 (USD MM)
Figure 19: AHF United Kingdom Sales by Treatment Setting- 2015-2022 (USD MM)
Figure 20: AHF United Kingdom Sales Patient Share by Treatment Setting- 2015-2022 (%)
Figure 21: Japan Acute Heart Failure Sales- 2015-2022 (USD MM)
Figure 22: AHF Japan Sales by Treatment Setting- 2015-2022 (USD MM)
Figure 23: AHF Japan Sales Patient Share by Treatment Setting- 2015-2022 (%)
Figure 28: Pipeline Trend in Acute Heart Failure
Cardiorentis
Novartis Pharmaceuticals
Bristol-Myers Squibb
Trevena
Amgen
Capricor Therapeutics
